Dermata Therapeutics Stock Performance
| DRMA Stock | USD 1.20 0.05 4.00% |
On a scale of 0 to 100, Dermata Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 0.82, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dermata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dermata Therapeutics is expected to be smaller as well. Please check Dermata Therapeutics' sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether Dermata Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating primary indicators, Dermata Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:15 | Last Split Date 2024-05-16 |
1 | Pre-market Movers SXTC, STIM, BIOA, UPC... - RTTNews | 12/09/2024 |
2 | Acquisition by Scott Kathleen D. of 5000 shares of Dermata Therapeutics at 1.38 subject to Rule 16b-3 | 01/13/2025 |
3 | Acquisition by David Hale of 78741 shares of Dermata Therapeutics at 1.27 subject to Rule 16b-3 | 01/21/2025 |
4 | Dermata Therapeutics announces 2.55M private offering | 01/22/2025 |
5 | Acquisition by David Hale of 78741 shares of Dermata Therapeutics subject to Rule 16b-3 | 01/23/2025 |
6 | Dermata to Present on BioPub on January 31, 2025 | 01/29/2025 |
7 | Crown Labs completes acquisition of Revance Therapeutics - MSN | 02/06/2025 |
| Begin Period Cash Flow | 6.2 M |
Dermata |
Dermata Therapeutics Relative Risk vs. Return Landscape
If you would invest 113.00 in Dermata Therapeutics on November 28, 2024 and sell it today you would earn a total of 7.00 from holding Dermata Therapeutics or generate 6.19% return on investment over 90 days. Dermata Therapeutics is currently generating 0.3007% in daily expected returns and assumes 6.3756% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Dermata, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dermata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dermata Therapeutics, and traders can use it to determine the average amount a Dermata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0472
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DRMA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.38 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Dermata Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dermata Therapeutics by adding it to a well-diversified portfolio.
Dermata Therapeutics Fundamentals Growth
Dermata Stock prices reflect investors' perceptions of the future prospects and financial health of Dermata Therapeutics, and Dermata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermata Stock performance.
| Return On Equity | -2.02 | ||||
| Return On Asset | -1.03 | ||||
| Current Valuation | 286.06 K | ||||
| Shares Outstanding | 5.36 M | ||||
| Price To Book | 1.40 X | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 10.63 M | ||||
| Cash Per Share | 1.05 X | ||||
| Total Debt | 1.62 M | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Earnings Per Share | (13.36) X | ||||
| Market Capitalization | 6.43 M | ||||
| Total Asset | 7.98 M | ||||
| Retained Earnings | (53.39 M) | ||||
| Working Capital | 6.36 M | ||||
About Dermata Therapeutics Performance
By analyzing Dermata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dermata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dermata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (1.14) | (1.20) | |
| Return On Assets | (0.88) | (0.92) | |
| Return On Equity | (1.41) | (1.48) |
Things to note about Dermata Therapeutics performance evaluation
Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dermata Therapeutics had very high historical volatility over the last 90 days | |
| Dermata Therapeutics may become a speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 24.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Crown Labs completes acquisition of Revance Therapeutics - MSN |
- Analyzing Dermata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dermata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermata Therapeutics' stock. These opinions can provide insight into Dermata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |